Edgewise Therapeutics (EWTX) Expected to Release Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.5320) per share and revenue of $119.23 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). On average, analysts expect Edgewise Therapeutics to post ($2.09) EPS for the current fiscal year and ($1.78) EPS for the next fiscal year.

Edgewise Therapeutics Stock Up 2.4%

NASDAQ EWTX opened at $40.49 on Thursday. Edgewise Therapeutics has a twelve month low of $15.94 and a twelve month high of $48.51. The business has a 50-day moving average price of $41.58 and a 200-day moving average price of $36.09. The firm has a market cap of $4.40 billion, a price-to-earnings ratio of -21.89 and a beta of 0.35.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Oppenheimer initiated coverage on Edgewise Therapeutics in a report on Thursday, July 9th. They issued an “outperform” rating and a $51.00 price target on the stock. Guggenheim increased their price objective on shares of Edgewise Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Thursday, October 15th. The Goldman Sachs Group lifted their price objective on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright reissued a “buy” rating on shares of Edgewise Therapeutics in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.33.

Insider Activity at Edgewise Therapeutics

In related news, CMO Joanne M. Donovan sold 2,919 shares of Edgewise Therapeutics stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $43.41, for a total transaction of $126,713.79. Following the completion of the sale, the chief marketing officer owned 8,625 shares in the company, valued at $374,411.25. This trade represents a 25.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan J. Russell sold 5,901 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $43.73, for a total transaction of $258,050.73. Following the completion of the sale, the insider directly owned 31,466 shares of the company’s stock, valued at approximately $1,376,008.18. This trade represents a 15.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 38,329 shares of company stock valued at $1,675,529 over the last ninety days. Company insiders own 21.30% of the company’s stock.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.